FRIDAY, April 26, 2019 (HealthDay News) — In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in Diabetes Care. Chantal Mathieu, M.D., PhD., from the University of Leuven in Belgium,…